

## Prostate Cancer Journal Club For Patients

**How can we predict how aggressive a localized Prostate Cancer will be and, based on the results, decide the most appropriate treatment?**

Learn about a new groundbreaking study, at this free Zoom Webinar presented on

**November 8<sup>th</sup> at 9:00 AM PDT (12:00 PM EDT)**

by Cleveland Clinic lead investigators **Jane K. Nguyen, MD. PhD.** and **Jesse McKenney, MD.** The Prostate Cancer Journal Club for Patients (PCJCP) is hosted by UroToday, the Prostate Cancer Foundation, and the University of California, San Francisco (UCSF) Patient Advocates. The paper will be discussed by Cornelia Ding, MD, and the discussion will be moderated by Matthew Cooperberg, MD, MPH from UCSF.

The study has identified microscopic features in prostate tumor tissue which can predict which patients are likely to progress to metastasis independent of Gleason grading. No patients in the study without these features progressed to metastasis. The pathology analysis was conducted on post-prostatectomy tissue.

To register for the webinar please visit:

[https://ucsf.zoom.us/webinar/register/WN\\_1VxxFsFDQ6yVdClc56sgYg](https://ucsf.zoom.us/webinar/register/WN_1VxxFsFDQ6yVdClc56sgYg)

### **About the Prostate Cancer Journal Club for Patients**

The PCJCP presents recent, game-changing medical papers relevant to prostate cancer patients while avoiding medical jargon and focusing on direct impact on patients' treatments.

The purpose is to educate patients to help them make better decisions about their prostate cancer care in collaboration with their doctors.

This will be our third PCJCP webinar. You can find recordings of our previous webinars here:

Webinar Topic	Webinar recording	Patient Q&A Recording
A 15-year randomized trial comparing surgery, radiation, and active surveillance	<a href="#">Presentation and Discussion</a>	<a href="#">Q&amp;A</a>
Comparing the effectiveness and side effects of three treatment options for men with high-risk disease and rapidly rising PSA after primary therapy: (1) ADT monotherapy, (2) Enzalutamide monotherapy, (3) Combined Enzalutamide and ADT	<a href="#">Presentation and Discussion</a>	<a href="#">Q&amp;A</a>